

# Eun-Jung Ko

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9584943/publications.pdf>

Version: 2024-02-01

11  
papers

513  
citations

933447

10  
h-index

1281871

11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

799  
citing authors

#	ARTICLE	IF	CITATIONS
1	Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5905-5930.	6.4	25
2	Discovery of an Allosteric Binding Site in Kinetoplastid Methionyl-tRNA Synthetase. <i>ACS Infectious Diseases</i> , 2020, 6, 1044-1057.	3.8	11
3	Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9318-9323.	7.1	119
4	Antitrypanosomal 8-Hydroxy-Naphthyridines Are Chelators of Divalent Transition Metals. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	12
5	3-Fluoro-4-hydroxyprolines: Synthesis, Conformational Analysis, and Stereoselective Recognition by the VHL E3 Ubiquitin Ligase for Targeted Protein Degradation. <i>Journal of the American Chemical Society</i> , 2018, 140, 9299-9313.	13.7	102
6	Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in <i>Leishmania donovani</i> . <i>ACS Infectious Diseases</i> , 2017, 3, 718-727.	3.8	22
7	Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against <i>Trypanosoma cruzi</i> . <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7284-7299.	6.4	31
8	Chloroform as a Hydrogen Atom Donor in Barton Reductive Decarboxylation Reactions. <i>Journal of Organic Chemistry</i> , 2013, 78, 6677-6687.	3.2	39
9	Reducing the Cost, Smell, and Toxicity of the Barton Reductive Decarboxylation: Chloroform as the Hydrogen Atom Source. <i>Organic Letters</i> , 2011, 13, 1944-1947.	4.6	51
10	Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2776-2780.	2.2	53
11	Inhibitors of the tyrosine kinase EphB4. Part 2: Structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5717-5721.	2.2	48